MAIA Doses First U.S. Patient in Phase 2 Lung Cancer Trial — MAIA Biotechnology, Inc.

Event summary

MAIA dosed the first U.S. patient in its Phase 2 THIO-101 trial for third-line non-small cell lung cancer (NSCLC).
The trial expansion is funded by a $2.3 million NIH grant.
Ateganosine, MAIA’s lead candidate, has FDA Fast Track designation and targets telomeres in cancer cells.
Prior data showed overall survival beyond 24 months in eight patients treated with ateganosine and a checkpoint inhibitor.

The big picture

MAIA’s U.S. trial expansion positions ateganosine as a potential third-line treatment for NSCLC, a critical unmet need in oncology. The NIH funding and FDA Fast Track designation underscore the strategic importance of telomere-targeting therapies in immuno-oncology. Success in this trial could validate MAIA’s approach and attract further investment in targeted immunotherapies.

What we're watching

Trial Execution: Whether MAIA can sustain momentum in the Phase 2 trial across four continents.
Regulatory Pathway: How the THIO-101 data may support a potential FDA accelerated approval.
Competitive Dynamics: The pace at which ateganosine differentiates itself in the crowded NSCLC treatment landscape.